Search Advanced

AIMS Biophysics

2016, Volume 3, Issue 4: 546-552. doi: 10.3934/biophy.2016.4.546
Previous Article Next Article
Editorial

Don’t forget the exogenous microbial transglutaminases: it is immunogenic and potentially pathogenic

  • 1.
    B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
  • 2.
    AESKU.KIPP Institute, Wendelsheim, Germany
  • Received: 10 November 2016 Accepted: 11 November 2016 Published: 15 November 2016

  • The exogenous microbial transglutaminase that imitates extensively the functions of the endogenous transglutaminases, is a universal protein cross-linker and translational modifier of peptides. The intestinal microbiome, dysbiome, pathobiome, probiotics and industrial processed food are at the origin of the luminal microbial transglutaminase daily cargo. It is hypothesized that those exogenous enzymes, are potential drivers of neurodegenerative and neuroinflammatory diseases via the gut luminal eco events. The substantial luminal activity of the enzyme, by cross-linking naive proteins, can potentially generate neo-epitopes that are not only immunogenic but may also be pathogenic, activating some harmful pathways in the cascade of chronic central brain diseases induction or progression. The harmful activities of microbial transglutaminase may represent a new pathway in the gut-brain axis and might open new therapeutical strategies to fight neurodegenerative conditions.

    Citation: Aaron Lerner, Torsten Matthias. Don’t forget the exogenous microbial transglutaminases: it is immunogenic and potentially pathogenic[J]. AIMS Biophysics, 2016, 3(4): 546-552. doi: 10.3934/biophy.2016.4.546

    Related Papers:

  • The exogenous microbial transglutaminase that imitates extensively the functions of the endogenous transglutaminases, is a universal protein cross-linker and translational modifier of peptides. The intestinal microbiome, dysbiome, pathobiome, probiotics and industrial processed food are at the origin of the luminal microbial transglutaminase daily cargo. It is hypothesized that those exogenous enzymes, are potential drivers of neurodegenerative and neuroinflammatory diseases via the gut luminal eco events. The substantial luminal activity of the enzyme, by cross-linking naive proteins, can potentially generate neo-epitopes that are not only immunogenic but may also be pathogenic, activating some harmful pathways in the cascade of chronic central brain diseases induction or progression. The harmful activities of microbial transglutaminase may represent a new pathway in the gut-brain axis and might open new therapeutical strategies to fight neurodegenerative conditions.


    加载中
    [1] Lerner A, Neidhöfer S, Matthias T (2015) Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond: Part A: TG2 double-edged sword: gut and extraintestinal involvement. Immunome Res 11: 101-105.
    [2] Lerner A, Neidhöfer S, Matthias T (2015) Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond. Part B: Anti-Transglutaminase 2 autoantibodies: friends or enemies. Immunome Res 11: 3-7.
    [3] Lerner A, Jeremias P, Neidhöfer S, et al. (2016) Antibodies against neo-epitope tTg complexed to gliadin are different and more reliable then anti-tTg for the diagnosis of pediatric celiac disease. J Immunol Methods 429: 15-20. doi: 10.1016/j.jim.2015.12.006
    [4] Gatta NG, Cammarota G, Gentile V (2016) Possible roles of transglutaminases in molecular mechanisms responsible for human neurodegenerative diseases. AIMS Biophysics 3: 529-545.
    [5] Lerner A, Matthias T (2015) Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 14: 479-489. doi: 10.1016/j.autrev.2015.01.009
    [6] Lerner A, Matthias T (2015) Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutr Rev 73: 544-552. doi: 10.1093/nutrit/nuv011
    [7] Kieliszek M, Misiewicz A (2014) Microbial transglutaminase and its application in the food industry. A review. Folia Microbiol 59: 241-250. doi: 10.1007/s12223-013-0287-x
    [8] Adapted from Freedonia Group Inc. World enzymes forecast for 2015 and 2020;Dec 2011.
    [9] Malandain H (2005) Transglutaminases: a meeting point for wheat allergy, celiac disease, and food safety. Eur Ann Allergy Clin Immunol 37: 397-403.
    [10] Elli L, Roncoroni L, Hils M, et al. (2012) Immunological effects of transglutaminase-treated gluten in coeliac disease. Hum Immunol 73: 992-997. doi: 10.1016/j.humimm.2012.07.318
    [11] Falini ML, Elli L, Caramanico R, et al. (2008) Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease. Dig Dis Sci 53: 2697-2701. doi: 10.1007/s10620-007-0191-9
    [12] Heredia-Sandoval NG, Islas-Rubio AR, Cabrera-Cha´vez F, et al. (2014) Transamidation of gluten proteins during the bread-making process of wheat flour to produce breads with less immunoreactive gluten. Food Funct 5: 1813-1818. doi: 10.1039/C4FO00118D
    [13] Matthias T, Jeremias P, Neidhöfer S, et al. (2016) The industrial food additive microbial transglutaminase, mimics the tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmun Rev DOI: 10.1016/j.autrev.2016.09.011.
    [14] Suwarnalata G, Tan AH, Isa H, et al. (2016) Augmentation of autoantibodies by Helicobacter pylori in Parkinson's disease patients may be linked to greater severity. Plos One 11: e0153725.
    [15] Çamcı G, Oğuz S (2016) Association between Parkinson's disease and Helicobacter Pylori. J Clin Neurol 12: 147-150. doi: 10.3988/jcn.2016.12.2.147
    [16] Dow CT (2014) M. paratuberculosis and Parkinson's disease—is this a trigger. Med Hypotheses 83: 709-712.
    [17] Scheperjans F, Aho V, Pereira PA, et al. (2015). Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30: 350-358. doi: 10.1002/mds.26069
    [18] Loeffler DA, LeWitt PA, Camp DM (2016) Nocardia asteroids-Induced movement abnormalities in mice: Relevance for Parkinson's disease? Mov Disord 31: 1134-1138. doi: 10.1002/mds.26711
    [19] Fasano A, Visanji NP, Liu LW, et al. (2015) Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 14: 625-639. doi: 10.1016/S1474-4422(15)00007-1
    [20] Dobbs SM, Dobbs RJ, Weller C, et al. (2016) Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol 22: 22-32.
    [21] Mulak A, Bonaz B (2015) Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 21: 10609-10620. doi: 10.3748/wjg.v21.i37.10609
    [22] Singhrao SK, Harding A, Poole S, et al. (2015) Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease. Mediators Inflamm 2015: 137357.
    [23] Bu XL, Yao XQ, Jiao SS, et al. (2015) A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol 22: 1519-1525.
    [24] Maheshwari P, Eslick GD (2016) Bacterial infection increases the risk of Alzheimer's disease: an evidence-based assessment. J Alzheimers Dis: 1-10.
    [25] Lerner A, Matthias T (2015) Food industrial microbial transglutaminase in celiac disease: treat or trick. International J Celiac Dis 3: 1-6.
    [26] Hasegawa S, Goto S, Tsuji H, et al. (2015) Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. Plos One 10: e0142164.
    [27] Julio-Pieper M, Bravo JA (2016) Intestinal barrier and behavior. Int Rev Neurobiol 131: 127-141. doi: 10.1016/bs.irn.2016.08.006
    [28] Snoek SA, Verstege MI, Boeckxstaens GE (2010) The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease. Expert Rev Gastroenterol Hepatol 4: 637-651.
    [29] César Machado MC, da Silva FP (2016) Intestinal barrier dysfunction in human pathology and aging. Curr Pharm Des 22: 4645-4650. doi: 10.2174/1381612822666160510125331
    [30] Buscarinu MC, Cerasoli B, Annibali V, et al. (2016) Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: a pilot study. Mult Scler Jun: 1352458516652498.
    [31] Yu YB, Li YQ (2014) Enteric glial cells and their role in the intestinal epithelial barrier. World J Gastroenterol 20: 11273-11280. doi: 10.3748/wjg.v20.i32.11273
    [32] Yu J, Pian Y, Ge J, et al. (2015) Functional and structural characterization of the antiphagocytic properties of a novel transglutaminase from Streptococcus suis. J Biol Chem 290: 19081-19092. doi: 10.1074/jbc.M115.643338
    [33] Yang XP, Fu JY, Yang RC, et al. (2016) EGFR transactivation contributes to neuroinflammation in Streptococcus suis meningitis. J Neuroinflammation 13: 274. doi: 10.1186/s12974-016-0734-0
    [34] Sun Y, Li N, Zhang J, et al. (2016) Enolase of Streptococcus suis serotype 2 enhances blood-brain barrier permeability by inducing IL-8 release. Inflammation 39: 718-726. doi: 10.1007/s10753-015-0298-7
  • Reader Comments
  • © 2016 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Biophysics
1.1 2.4

Metrics

Article views(5577) PDF downloads(1008) Cited by(16)

Preview PDF
Download XML
Export Citation
Article outline

Figures and Tables

Tables(1)

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog